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A B S T R A C T
By their definition, inadvertent exposure to endocrine disrupting compounds (EDCs) intervenes with the en-
docrine signalling system, even at low dose. On the one hand, some EDCs are used as important pharmaceutical
drugs that one would not want to dismiss. On the other hand, these pharmaceutical drugs are having off-target
effects and increasingly significant exposure to the general population with unwanted health implications.
Flutamide, one of the top pharmaceutical products marketed all over the world for the treatment of prostate
cancer, is also a pollutant. Its therapeutic action mainly depends on targeting the androgen receptors and in-
hibiting the androgen action that is essential for growth and survival of prostate tissue. Currently flutamide is of
concern with respect to its categorization as an endocrine disruptor.
In this work we have developed a physiologically based pharmacokinetic (PBPK) model of flutamide that
could serve as a standard tool for its human risk assessment. First we built the model for rat (where many
parameters have been measured). The rat PBPK model was extrapolated to human where the re-parameteriza-
tion involved human-specific physiology, metabolic kinetics derived from in-vitro studies, and the partition
coefficient same as the rat model. We have harmonized the model by integrating different sets of in-vitro, in-vivo
and physiological data into a PBPK model. Then the model was used to simulate different exposure scenarios and
the results were compared against the observed data. Both uncertainty and sensitivity analysis was done.
Since this new whole-body PBPK model can predict flutamide concentrations not only in plasma but also in
various organs, the model may have clinical applications in efficacy and safety assessment of flutamide. The
model can also be used for reverse dosimetry in the context of interpreting the available biomonitoring data to
estimate the degree to which the population is currently being exposed, and a tool for the pharmaceutical
companies to validate the estimated Permitted Daily Exposure (PDE) for flutamide.
1. Introduction
Flutamide is one of the top pharmaceutical products marketed
universally all over the world for the treatment of prostate cancer. Its
therapeutic action mainly depends on its metabolite flutamide hydro-
xide, which is a competitive inhibitor of endogenous androgens for
binding to their receptors in prostate (Brogden and Clissold, 1989).
Several rat studies revealed flutamide has off target effects, such as
decreased weight of the accessory gland, alteration in sex hormone
levels in the male rat, and prolongation of the oestrous cycle in female
rats (Shin et al., 2002; Toyoda et al., 2000a). Miyata et al. (2002) have
linked flutamide exposure to its endocrine related effects in rats. Pa-
tients treated with flutamide at its therapeutic dose are always at a
higher risk of liver toxicity (Brahm et al., 2011; Tavakkoli et al., 2011),
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which is presumed to be its idiosyncratic adverse effect. Consequent to
an OECD-guideline, repeated-dose, screening for endocrine disruptors
compounds (EDCs), flutamide was listed as one of the EDCs (Toyoda
et al., 2000b). Endocrine disruptor's chemicals can elucidate toxicity
even at low dose (Blumberg et al., 2011). The estimated no observed
effect level (NOEL) for flutamide is 0.25 mg/kg/day (Toyoda et al.,
2000b). Mimicking endogenous hormones is considered to be one of the
important mechanisms of EDCs.
The current guideline set by European Medicines Agency (EMEA)
requires that pharmaceutical companies relate the Permitted Daily
Exposure (PDE) (EMEA, 2014) of API (active pharmaceutical in-
gredients) to their specific toxicological end points. Residuals of active
chemicals generated during the manufacturing cycle and exposure to
humans via cross contaminated medicinal products should be con-
sidered for estimating the PDE (Hayes et al., 2016). Recently flutamide's
PDE of 0.025 mg/day was established as safe dose in the context of
reproductive and development disorders end points (Zacharia, 2017).
Knowing the target tissue concentration and its further integration to
the toxicodynamic model should help to predict toxicological endpoints
(Sharma et al., 2017a, 2017b).
Upon rapid absorption after oral administration, flutamide under-
goes extensive hepatic first-pass metabolism in humans generating
several metabolites (Katchen and Buxbaum, 1975). Flutamide meta-
bolites differs between species due to different tissue distribution and
different enzyme activities (Kobayashi et al., 2012a, 2012b). Liver
CYP1A2 metabolizes flutamide to flutamide hydroxide (Flu-OH)
(Radwanski et al., 1989; Shet et al., 1997; Sjo et al., 2009; Sjögren et al.,
2014a). Other metabolites include 4-nitro-3-(trifluoromethyl)-aniline
(FLU-1) and 2-methyl-N-(4′-amino-3′ [trifluoromethyl] phenyl) propa-
namide (FLU-6) (Kobayashi et al., 2012a, 2012b; Wen et al., 2008).
Wen et al. (2008) showed that NADPH: cytochrome P450 reductase
(CPR) was involved in producing FLU-6 in liver by nitro reduction of
flutamide, which enhances hepatocytes cytotoxicity. Complete elim-
ination of flutamide and its metabolites takes 5 days according to an in-
vivo human study (Katchen and Buxbaum, 1975).
PBPKs models have been applied successfully in toxicology and also
welcomed by pharmaceutical companies as an integral tool in drug
discovery and development.(Jones et al., 2015; Zhuang and Lu, 2016;
Sharma et al., 2018a, 2018b). Not only do they estimate target tissue
concentrations, but they also allow interspecies extrapolation, in-
traspecies dose interpolation, and exposure dose reconstruction. PBPK
models are mathematical representations of compartments corre-
sponding to the various physiological organs of the body, linked by the
circulating blood system. Each compartment is described by a tissue
volume and blood flow rate that is specific to the species of interest.
PBPK describes the bio-distribution (absorption, distribution,
metabolism and elimination, referred as ADME) and generates time
course profiles of chemicals inside the body. A semi-physiologically
based biopharmaceutical model has been developed in human for the
injectable flutamide hydroxide to estimate the local distribution of the
chemical to prostate tissue (Sjögren et al., 2014a). However, to our
knowledge there is no full scale PBPK model for flutamide, neither for
rats nor for humans.
This article presents physiologically based pharmacokinetic (PBPK)
models predicting the time variant concentrations of flutamide in
plasma and other organs upon oral dosing in rats and humans.
Harmonizing the in-vitro and the animal data using IVIVE and cross
species extrapolation methods respectively for the development of
whole body PBPK model has shown in this manuscript. The models
were used to simulate single and multiple dose scenarios. The simulated
data were compared against the data observed in plasma. In the case of
the human PBPK, data referring to the flutamide and its metabolite Flu-
OH were taken into consideration. Both the bottom up and the top
down approach were applied to the development of the model. Prior
mean parameter values were obtained either from the published lit-
erature or via in-silico or in-vitro and in-vivo experiments, whilst ac-
counting for uncertainties in the range of± 1 to±1.5 standard de-
viations. After a sensitivity analysis, the most uncertain yet influential
parameters were distributed statistically for Monte Carlo simulations.
We conclude that the models should be suitable for the assessment of
flutamide as endocrine disruptor.
2. Material and methods
2.1. PBPK model development
For both rat and human our PBPK model comprises nine compart-
ments, i.e. gut, liver, plasma, lungs, kidney, fat, gonads, prostate and a
compartment representing the rest of the body (Fig. 1). The model is
flutamide-specific which includes prostate and gonads; flutamide is
used in prostate cancer therapy. The exchange of the flutamide between
blood and tissue in each organ is described by flow limited processes i.e.
we implemented a perfusion rate-limited PBPK model (not permeability
limited). This model works under the assumption that total chemical
concentration in the tissue and in the plasma at steady state are in
equilibrium with each other. First the model was developed in rats and
then extrapolated to humans. Because for the animal models there are
more data sets available remaining unmeasurable parameters can be
fitted more readily to one group of data sets, whilst using remaining
data sets for validation. Accordingly, our strategy was to make an op-
timal model for rat and then extrapolate this to the human. Oral dosing
is considered to be the main route. After an oral exposure, flutamide is
Fig. 1. Minimal PBPK model structure for flutamide and its metabolite flutamide hydroxide. Six tissues, each with a concentration (C) of flutamide (and similarly for
flutamide hydroxide) are connected through the blood (plasma). Each compartment has a passive uptake from (as indicated near the beginning of each arrow,
reactions re7, re9, re10,re12, re14, re21) and an active release (re6, re8, re11, re22, re13, re15) into the blood, but only the liver can metabolize (reaction re3, re4,
re5) and destroy it in its cytosol. re18, re19 corresponds to flutamide and its metabolite flu-OH protein binding. re16, re17 corresponds to urinary excretion of
flutamide and its metabolite flu-OH. “M1” corresponds to flutamide hydroxide and “re” corresponds to reactions.
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rapidly absorbed by the system, in a process described using a first
order rate constant. Plasma protein binding of flutamide and of its main
metabolite (flutamide hydroxide; considered only for human model)
was made to conform to the experimentally measured fixed ratio va-
lues. The fraction of chemical not bound to plasma proteins is the only
fraction of a chemical that is available for transport into organs for
metabolism and for clearance.
Distribution parameters such as partition coefficients describe
steady state ratios of the concentrations in the plasma and the different
organs. Partition coefficients for different organs were derived from the
detailed rat in-vivo studies (Asakawa et al. (1995a) using AUC (area
under the curve) data. The same partition coefficients were then used
for both rat and human PBPK model development. Elimination path-
ways included both chemical metabolism and its urinary excretion. The
metabolism of the flutamide was described using the Michaelis-Menten
and Hill equations. Data from literature in-vitro cell line studies for
both rat and human were scaled to respective in-vivo using IVIVE ap-
proach (in-vitro in-vivo extrapolation) (Howgate et al., 2006a). Vali-
dation of the rat model included several in-vivo kinetic data sets for rat
resolving 7 compartments, i.e. plasma, liver, lung, kidney, fat, gonads
and prostate. For the validation of the human model, kinetic data sets
for flutamide and its metabolite flutamide hydroxide in plasma
(Radwanski et al., 1989) were used, as well as multiple dose scenario
kinetic data sets (Radwanski et al., 1989). Concentrations of the che-
mical in any compartment were estimated by applying Eq. (1) without
metabolism; however metabolic equation, Eq. (3), is included in the
respective compartment responsible for metabolism of chemical. A
more detailed model description including the equations used for each









where, Ci is the concentration in the tissue i (μg/L), Qi is the blood flow
in the tissue i (L/h), Ca is the arterial concentration (μg/L), Ki:p is the
partition coefficient of tissue i, and Vi is the volume of the tissue i (L).
The blood is considered to flow into a well-mixed extracellular com-
partment in the tissue where the drug is at partition equilibrium with
the intracellular drug. Should there be active drug efflux or influx
pumping, this is rather a partition steady state where the partition
coefficient becomes dependent on the cells' energy state.
2.2. PBPK model parameterization
PBPK model parameterization requires physiological parameters,
physiochemical properties (fraction unbound and partition coefficient,
estimated either by in silico or animal experimentation), and bio-
chemical parameters such as for metabolism (Vmax and Km and other
relevant kinetic constants). Our baseline model was for rat and we
extrapolated this to the human by adapting the tissue volumes, blood
flows through the tissues and the Vmax per unit microsomal protein,
and the fraction of microsomal protein per organ on the basis of ex-
perimental data. The partition coefficients were considered the same for
rat and human.
All the physiological parameters such as blood flow to tissue as a
fraction of cardiac blood flow and tissue volume as a fraction of body
weight for both rats and human are provided in Table A.1 and A.2
Supplementary Information (SI). Chemical rate constants and metabolic
parameters are provided in Table 1. We have estimated prostate volume
and blood flow from the reported literature data, for humans (Inaba,
1992; Sjögren et al., 2014b) and for rats (Shimizu et al., 2015). As per
requirement of PBPK, these data were converted into fraction of body
weight and fraction of cardiac blood flow, respectively and are pro-
vided in Table A.1 and A.2 (SI)). The oral absorption process for the
flutamide was described through a first order absorption rate constant
0.62 h-1 (Xu and Li, 1998). The same absorption rate was taken for
single and multiple oral doses simulations of the human PBPK model.
We interpreted detailed rat in-vivo data reported in Asakawa et al.
(1995a, 1995b) through a method introduced by Gallo et al. (1987) and
effectively adapted by others (Lin et al., 2016), This method uses the
trapezoidal rule to derive tissue partition coefficients (Kpt) from the
AUC (area under the curve) observed in in-vivo animal kinetic profile








where, −AUCtissue (0 48) represents the area under the curve for the tissue
concentration-time curves from 0 to 48 h −AUCplasma (0 48) represents the
area under the curve for the plasma concentrations-time profile from 0
to 48 h. The values of partition coefficients for different organs used in
our rat PBPK model are provided in Table 1.
The average binding percentage of flutamide with plasma protein
was reported for rats and human as 60.6 and 91.9%, respectively
(Asakawa et al., 1995a). The reported mean value of 95% for Flu-OH
(flutamide hydroxide) for human was used to derive the fraction un-
bound for Flu-OH, which has also been previously used by Sjögren et al.
(2014a) for the development of a semi physiologically based pharma-
cokinetic model. We assumed that intracellularly the same fraction of
flutamide is bound to intracellular proteins. The fractional unbound
(fu) for both flutamide and its metabolite flutamide hydroxide are
provided in Table 1.
Flutamide metabolism is described as a saturable process utilizing
the Michaelis-Menten equation (Eq. (3)) with parameters Vmax (max-
imum velocity of metabolic reaction) and Km (1/affinity, i.e. con-
centration at which reaction occurs at half maximal rate). The reported
in-vitro Vmax values for the tissue microsomal fraction were scaled to
in-vivo values using the IVIVE approach (Howgate et al., 2006b),
whereas Km values were kept the same as the in-vitro value. The in-
vitro in-vivo extrapolation (IVIVE) approach utilizes physiological
specific parameters such as tissue specific microsomal protein content,









where, Ct is the corresponding concentrations in tissue and fu is the
fraction unbound.
 vAmets is the rate of production of metabolites.
= ∗ ∗Vmax Vmax MSPPGT V BW( )/invivo invitro tissue .75 (4)
where, MSPPGT is the microsomal protein per gram tissue; Vtissue is the
volume of tissue; BW is the body weight and its power to .75 is to
normalize the scaled Vmax for different body weight persons.
The in-vitro data such as Vmax and Km for flutamide metabolism in
rats were taken from Yuki Kobayashi et al. (2012a, 2012b). This study
reported on flutamide metabolism in different tissue cell lines. The in
vitro measured specific activity (Vmax) for liver, lung and kidney
provided in Table 1 were scaled to whole body in order to obtain the in-
vivo specific intrinsic clearance. For the development of the human
PBPK model, the biochemical parameters such as Vmax and Km de-
scribing metabolism of flutamide into 3 different metabolites (Fig. 2)
were taken from in-vitro hepatic cell line studies (Kobayashi et al.,
2012a, 2012b; Sjo et al., 2009; Wen et al., 2008); the corresponding
values are provided in Table 1. Eq. (3), basically involves the extra-
polation of the specific activity from in-vitro measured to in-vivo whole
body, used for the both rat and human using species specific physio-
logical data such as microsomal protein content of tissue, tissue volume
and body weight provided in Table A. (1& 2) (SI). Our human PBPK
model involves three metabolic reactions producing three different
metabolites. However, only flutamide hydroxide, which is the major
metabolite, was distributed to plasma from the liver site using the same
partition coefficient to that of the parent compound. Due to lack of
R.P. Sharma, et al. Environmental Research 182 (2020) 108948
3
specific data on the generation of different metabolites, no metabolites
were included in the current rat PBPK model. However clearance of
flutamide is considered in that model, including its metabolism in rat
lung, rat liver and rat kidney as reported by Yuki Kobayashi et al.
(2012a, 2012b) in in-vitro cell line studies. Elimination rate constants
for both flutamide and flutamide hydroxide were visually optimized to
fit the plasma data of human studies carried out by (Radwanski et al.,
1989). The flutamide elimination rate constant was needed to optimize
in order to match the observed data knowing the fact that there are
some unknown flutamide catabolism pathways.
2.3. Sensitivity analysis
A sensitivity analysis was carried out both for the rat and for the
human PBPK model. The R package FME was used, which measures the
alteration in model output for variable of interest by changing each
parameter by 1% change up and down whilst keeping the other ones
constant. Detailed information about the functions of FME can be found





















Where, S flutamide t j[ ( )], is the sensitivity of the flutamide
Table 1
Flutamide chemical and biochemical specific parameter values and its statistical distributions. LN: LOG NORMAL LN (a,b) means a = LN (mean) and
b = standard deviation in LN space.
Parameters Symbols Units Values or distributions References
Partition coefficients-
Liver/Plasma Kpt:liver/plasma LN (5.57, 1.5) a
Lung/Plasma Kpt:lung/plasma LN (1.65, 1.1) a
Kidney/Plasma Kpt:kidney/plasma – LN (2.63, 1.5) a
Fat/Plasma Kpt:fat/plasma – LN (2.78, 1.1) a
gonads/Plasma Kpt:gonads/plasma – LN (1.7, 1.5) a
prostate/Plasma Kpt:prostate/plasma – LN (2.17, 1.1) a
Rest of the body/Plasma Kpt:restbody/plasma – LN (5.57, 1.1) a
Liver/Plasma (FLU-OH) Kpt:liver/plasmaM1 – LN (5.57, 1.5) a
Absorption and elimination parameters
Unbound fraction in plasma (Flutamide) fu – 0.09 Asakawa et al. (1995a)
Unbound fraction in plasma (Flu-OH) fu1 – 0.05 Sjogren et al. (2014a, 2014b)
Oral absorption rate kgut 1/h LN (0.64, 1.1) a
Elimination rate kurine 1/h LN (1.25, 1.5) optimized
Elimination rate (FLU-OH) kurineM1 1/h LN (1.85, 1.5) optimized
Metabolic parameters for human
Flu to Flu-OH maximum reaction value VmaxlivM1_invitro μg/min/mg MSP LN (0.079,1.1)b Sjo et al. (2009)
Conc. at half maximum value KmliverM1 mg/L 1.113 Sjo et al. (2009)
Flu to Flu-6 maximum reaction value VmaxlivM2_invitro μg/min/mg MSP LN (0.052, 1.1) b Wen et al. (2008)
Conc. at half maximum value KmliverM2 mg/L 23.754 Wen et al. (2008)
Flu to Flu-1 maximum reaction value VmaxlivM3_invitro μg/min/mg MSP LN (0.31, 1.1) b Kobayashi et al. (2012a)
Conc. at half maximum value KmliverM3 mg/L 82.863 Kobayashi et al. (2012a)
Metabolic parameters for rat
Unbound fraction in plasma fu – LN (0.4, 1.5) Asakawa et al. (1995a)
Flu metabolism in liver VmaxlivM1_inviro μg/min/mg MSP LN (0.8, 1.2) b Kobayashi et al. (2012a)
Conc. at half maximum value KmliverM1 mg/L 276 Kobayashi et al. (2012a)
Flu metabolism in kidney VmaxkidM1_invitro μg/min/mg MSP LN (0.75, 1.1) b Kobayashi et al. (2012a)
Conc. at half maximum value KmkidneyM1 mg/L 1600 Kobayashi et al. (2012a)
Flutamide metabolism in lung VmaxlungM1_invitro μg/min/mg MSP LN (0.028, 1.1) b Kobayashi et al. (2012a)
Conc. at half maximum value KmlungM1 mg/L 193 Kobayashi et al. (2012a)
Oral absorption rate kgut 1/h LN (0.64, 1.1) a optimized
Renal clearance ClR L/h LN (0.07, 1.5) c optimized
a Derived from sources explained in parameterization section 2.2 and using same value in case of both rat and human PBPK model.
b Parameters are scaled to whole body species prior to use in model.
c Rat glomeration filtration rate was considered.
Fig. 2. Schema for human flutamide metabolism; Liver CYP1A2 metabolizes flutamide into flutamide hydroxide, main metabolite. Deacetylation of flutamide by
carboxylesterase generates Flu-1. Reduction of aromatic nitro group into amino group by cytochrome reductase results in conversion of Flutamide to FLU-6.
R.P. Sharma, et al. Environmental Research 182 (2020) 108948
4
Fig. 3. (a–g): PBPK model predictions of flutamide concentration in various rat compartments following 5 mg/kg oral dose of flutamide. Blue lines: 2.5 and 97.5
percentiles; Gray lines: 20 simulations chosen at random from the ensemble of 15,000 iterations where the parameters were chosen at random within the confines of
their log normal distribution parameterized as provided in Table 1. Red lines: median prediction taken from the ensemble of 15,000 iterations; the green dots indicate
the mean concentrations and black lines indicate the mean± sd reported in (Asakawa et al. (1995a). For the fat compartment (e), the data for 48 h was not available.
(For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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concentration to any time-independent parameter pj, normalized by
both the model variable and the parameter value and thereby di-
mensionless. pj is any parameter of the PBPK model and flutamide t[ ( )]
is the scaling of variable i.e. flutamide plasma concentration.
These sensitivity functions collapsed into a summary of sensitivity
values. The magnitude of the time-averaged sensitivity values were
used to rank the parameters. This includes the absolute values of the
sensitivity coefficients |S| i.e. −flutamide(t) flutamide(t)(pj) termed as
least absolute deviation, the average of their squares S2 termed as least
square error, and their average Smean (t), their lowest Smin and their
















There are two different time average S coefficients: one takes the





































The PBPK model was developed using ordinary differential equa-
tions describing the kinetics of flutamide. The equations were written in
the GNU MCSim modeling language (Bois and Maszle, 1997) and solved
by numerical integration with the GNU MCSim, using the R platform.
And a priori information was taken from in vitro and in-vivo experi-
ments reported in the literature. Sensitivity analysis considered mean
values of parameters. Monte Carlo (MC) simulations were performed to
estimate the impact on model predictions of uncertainty in all of the
rate constants, the partition coefficients, and the Vmax of the metabo-
lizing enzyme. MC simulation consisted of 15,000 iterations and each
corresponded to simulation of the model equations with parameter set
defined by a random sample from the probability distributions provided
in Table 1. The observed experimental data were used for model cali-
bration and evaluation. The model was considered to be fit, if all the
observed data fell within the range of output simulation between the
2.5th and 97.5th percentile.
2.5. Calibration and evaluation of PBPK model
First the calibration and then validation of the model was done
using data on several compartments. Most of the data were taken from
the in-vitro and in-vivo experiments. The unknown parameters prior
values were first calibrated against the observed in-vivo data and the
logarithms of their values were then assigned a normal distribution. To
validate the rat PBPK model, rat experimental data for different organs
were used from the Asakawa et al. (1995a) study involving a single oral
administration of flutamide at a dose 5 mg/kg. The mean weight of the
rats was 250 g. The time course profile of flutamide concentration in
plasma and different organs were recorded at 0.5, 2, 8, 24 and 48 h. The
output concentrations data were expressed as the mean (μg/ml) ± SD.
The units were converted into μg/L in order to make simulation output
and observed data uniform. The kinetic profile for seven compartments,
namely plasma, liver, lung, kidney, fat, gonads and prostate were used
to evaluate the performance of the model.
An experimental human study by Radwanski et al. (1989) in which
volunteers were orally administered 0.25 g of flutamide was used to
evaluate the human PBPK model. The subject characteristics include
mean weight, height and age of 89 kg, 180 cm and 66 year,
respectively. The study involved two case scenarios: One was admin-
istration of a single oral dose of 0.25 g and then measuring the time
course profile of flutamide and its metabolite flutamide hydroxide in
plasma at 0, 0.5, 1, 1.5, 2, 3, 4, 6 h and at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12,
16, 24 h, respectively. The second scenario included multiple dosing,
i.e. on the first day a single oral dose of 0.25 g, then a dose of 0.25 g
three times a day from the 2nd to the 8th day. The observed con-
centration in plasma on the 6th and the 9th day were recorded for both
flutamide and flutamide hydroxide. The data are expressed in mean
(ng/ml~μg/L) and SD.
3. Results
3.1. Rat PBPK model
The rat PBPK model was used to simulate the experimental data
obtained by Asakawa et al. (1995a) for seven different compartments
after oral administration of 5 mg/kg to the rat. The model prediction
results are presented in Fig. 3(a–g) for 20 random predictions; their
median (red), and their two extremes corresponds to 2.5 and 97.5
percentiles (blue). The green points represent the experimentally ob-
served mean concentrations, the black bars represents± standard de-
viation. Overall, the experimental in-vivo time course concentrations
for several organs Fig. 3(a–g) were adequately predicted by the model.
In most of the compartments, model slightly under-predicted the rate of
appearance i.e. initial observed experimental points are at or near the
97.5th of the modeling percentile. This indicates that model prediction
uncertainty is still much higher than experimental uncertainty: the
model uncertainty exceeds the experimental noise and it should
therefore be possible to improve the model further by a more precise
determination of its parameters. The under-prediction of initial time
points by the model could be due to the under-estimation of the gut
absorption rate constant parameter. This fact is further supported by
the sensitivity results (Table 2), where the gut absorption rate constant
parameter has high positive sensitivity coefficient among all other
parameters. However, terminal experimental points are close to the
predicted median line.
The results also show that the flutamide concentrations in plasma
(Fig. 3a) were lower than in the other compartments. Fig. 4 (a) shows
the flutamide concentrations in various organs relative to the con-
centration in the prostate, again as a function of time. An optimal drug
against prostate cancer should have a much lower concentration in
gonads and liver, i.e. in organs where this drug is suspected to have side
effects other than in prostate, where it is supposed to be active against
the tumor. And it should have a much lower concentration in liver,
where it is removed by metabolism and where metabolic products may
cause idiosyncratic liver damage. None of this is true, neither for the
model nor for the experimental results. Endocrine related adverse ef-
fects shown by flutamide are thought to be mediated by its action in
gonads. Here PBPK model shows that flutamide concentrations in the
gonad and also in liver is higher than in the plasma, indicating im-
portance of knowing target concentration and thus risk assessment
based on tissue dosimetry model.
Fig. 4 (b) shows the results of AUC as a function of time for plasma,
liver, gonads and prostate. After an hour, these organs have had their
90% integral dose. This suggests that multiple low dose would be ad-
vantageous than compare to high dosing once a day. With multiple
dosing scenarios, one may able to maintain the therapeutic con-
centrations at target site with minimal exposure to off target organ such
as gonads. In contrast single high dosing of flutamide could increase its
non-target organs exposure where drug flushes out slowly (mean re-
sidence time is higher).
3.2. Human PBPK model
When simulating tissue concentrations for the human model, the
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partition coefficients parameters were kept the same than for rat model,
whereas the rate constant for absorption was estimated by using the
reported (Xu and Li, 1998) absorption half-life of 1–2 h. Fig. 5 (A-B)
represents the simulated time course of flutamide and its metabolite
flutamide hydroxide in plasma following a single oral dose of 0.25 g.
Remarkably, for this extrapolation from rat to human, the 2.5–97.5
percentile of the distribution of the modeling results still includes the
experimental results. For flutamide itself, the variation in model pre-
diction is now virtually equal to the experimental variability, sug-
gesting that no further model improvement is called for. Here the ex-
perimental reproducibility should be enhanced if it is due to
experimental error, or, if it is due to biological variability between in-
dividual humans, we therefore should move to individualized models.
For flutamide hydroxide the model variability is still a wee bit higher
than the experimental variability; here some parameters need to be
improved.
Fig. 5 (A) shows a small over-prediction by the model of the fluta-
mide concentrations at early times after administration, as compared to
the experimental results. At early times, flutamide hydroxide is under-
predicted. This suggests that the model underestimates flutamide cat-
abolism to flutamide hydroxide.
The flutamide concentrations decreased within 24 h to significantly
lower levels. Therefore, we also simulated repeated dosing of the drug.
All the parameters were keep the same for multiple dose scenario si-
mulations, which involved 1st day single dose of 0.25 g and then three
times in day from 2nd to 8th day oral dose of 0.25 g and the results are
presented in Fig. 6(A-B). Again, all the observed mean points are within
the simulated range shows data agreement between simulated and
observed. The increase in concentration of flutamide and flutamide for
multiple oral doses was captured by the model which has been also
observed in human experimental study.
Further simulation for 48 h after a single oral dose of 0.25 g for
several compartments keeping all parameters equal is presented in
Fig. 7 (A–F). As expected, initially the liver gets a very high con-
centration of flutamide and then decreases very rapidly as liver actively
metabolizes it. Flutamide concentrations into fat and gonads are much
lower than in other compartments. Fig. 7 (D & E) kinetics profile shows
that flutamide concentration in these two organs might have longer
residence time. This observation should be further investigated, which
might be very important as the endocrine effects of flutamide are
mainly targeted to the gonads.
3.3. Parameter sensitivity
A sensitivity analysis was carried out for all the parameters that
were used for the development of the PBPK model. The summarized
Table 2
Sensitivity results for both the rat and human PBPK model. It includes |S| and |S2| norm, mean, minimum, maximum, and ranking. Ranking of parameter sensitivity
coefficient was done based on |S| that measures least absolute deviation of output (here flutamide plasma concentration).
Response variable: Flutamide Plasma concentrations in rat
(A) Summary statistics of parameters' sensitivities
Parameters |S| |S2| Smean Smin Smax Rank
kgut 1.826 0.134 0.3 −1.04 63.48 1
fu 1.581 0.048 −1.579 −3.028 0.564 2
kurine 1.076 0.033 −1.076 −2.199 0 3
K_kidney_plasma 1.069 0.033 −1.069 −2.178 0 4
K_restbody_plasma 0.742 0.023 0.607 −0.533 1.643 5
KmliverM1 0.736 0.02 0.736 0 0.974 6
K_liver_plasma 0.616 0.017 −0.616 −0.960 0 7
VmaxliverM1 0.409 0.011 −0.409 −0.542 0 8
K_fat_plasma 0.142 0.004 0.116 −0.095 0.318 9
K_gonads_plasma 0.008 0 0.006 −0.004 0.023 10
K_lung_plasma 0.007 0 0.006 −0.009 0.015 11
K_prostate_plasma 0.003 0 0.002 −0.006 0.005 12
KmkidneyM1 0.002 0 0.002 −0.001 0.003 13
VmaxkidneyM1 0.001 0 −0.001 −0.008 0.004 14
KmlungM1 0 0 0 −0.002 0.001 15
VmaxlungM1 0 0 0 0 0 16
K_liver_plasmaM1 0 0 0 0 0 17
(B) Summary statistics of parameters' sensitivities
Response variable: Flutamide Plasma concentrations in human
k_liver_plasma 0.987 0.037 −0.987 −0.997 0 1
vmaxliverM1 0.95 0.035 −0.95 −0.992 0 2
kmliverM1 0.904 0.034 0.904 0 0.928 3
k_restbody_plasma 0.513 0.021 −0.513 −0.721 0 4
kurine 0.408 0.016 −0.408 −0.510 0 5
kgut 0.348 0.020 −0.239 −1.126 1.006 6
fu 0.294 0.014 −0.065 −0.837 0.798 7
vmaxliverM3 0.053 0.002 −0.053 −0.057 0 8
kmliverM3 0.053 0.002 0.053 0 0.057 9
k_fat_plasma 0.051 0.002 −0.051 −0.071 0 10
vmaxliverM2 0.031 0.001 −0.031 −0.034 0 11
kmliverM2 0.031 0.001 0.031 0 0.034 12
k_lung_plasma 0.023 0.001 0.017 −0.024 0.051 13
k_kidney_plasma 0.01 0.001 0.006 −0.048 0.032 14
k_prostate_plasma 0.001 0 0.001 −0.004 0.005 15
k_gonads_plasma 0 0 0 −0.00012 −0.0002 16
k_liver_plasmaM1 0 0 0 0 0 17
kurineM1 0 0 0 0 0 17
fu1 0 0 0 0 0 17
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table results for the rat and human PBPK models are provided in
Table 2. It includes |S| and |S2| norm, mean, minimum, maximum, and
ranking. The table summarizes the statistics of the normalized and di-
mensionless parameter sensitivity results. Ranking of parameter sensi-
tivity coefficient was done based on |S| that measures least absolute
deviation of output (here flutamide plasma concentration).
Sensitivity coefficients results for different parameters are provided
in Table 2 (A-B). In turn Fig. 8 (A–B) represents the mean sensitivity
coefficients. As expected, the sensitivity coefficients of the flutamide
concentrations to urine is negative: urine secretes the compound. In
humans, the flutamide level in plasma is modelled to be strongly in-
fluenced by diuresis: its sensitivity coefficient is −1, meaning that a
10% activation of urination should decrease the flutamide level by
10%. Surprisingly, the sensitivity towards the gut activity is much
smaller than expected in the rat model and even negative in the human.
The latter finding suggests that the activation of flutamide uptake from
the gut cause a decrease in the level of flutamide in the plasma. The
explanation is that increased liver uptake of the flutamide activates
flutamide metabolism earlier; initially the plasma flutamide con-
centration may be higher, but the drug is removed more quickly from
the body by liver detoxification (first pass metabolic effect). Indeed, in
the human the plasma flutamide concentration depends strongly on the
drug detoxification reaction in liver, at a sensitivity coefficient of
around −1. This shows that flutamide metabolism is an important
process for determining the flutamide concentration in plasma. The
mean sensitivity coefficient of Vmax is negative and Km is positive. This
result suggests that adding these two parameters have opposite effect
on flutamide concentration. Statistical distribution of both parameters
simultaneously would result in compensation into the output variable
i.e. flutamide plasma concentrations. Thus, we restricted probability
distributions to Vmax only for the uncertainty analysis, so that it would
not influence the output result.
The expectation that the binding fraction to proteins (fu) has a ne-
gative control over the free plasma flutamide concentrations was ex-
pected because the binding will lower its free concentration. Likewise
one should expect that the partition coefficients exert negative control
on the plasma flutamide concentrations. The sensitive coefficient at min
and max of partition coefficients for liver, kidney exert negative effect
or no effect (zero) on flutamide concentration (Table 2(A)). Indeed,
both the liver and the kidney causes clearance of flutamide; in other
word, flutamide is not retained in these organs. But for the other tissues
such as fat, gonads, lung and prostate, sensitivity coefficient ranges
from negative to positive. This indicates that their partition coefficient
exert a positive control on the flutamide concentration at the later
times. It could be explained by the fact that drug might be retained for
longer in these organs, as these are non-metabolizing organs. Accord-
ingly to the results showed in Table 2 (B), the maximum sensitivity
coefficient values are in this order: Rest of body > Fat > Lung >
Prostate > Gonads.
4. Discussion
The present study is the first attempt to develop a two species (Rat
and Humans) PBPK model simulating the concentrations of flutamide in
various tissues following a single or repetitive oral dose. The model was
parameterized on the basis of harmonization of a different set of data
such as species-specific physiological data, physicochemical data and
independent biochemical data on metabolism such as in-vitro data for
both rats and humans. The human model was made specific by inserting
human specific data for enzyme activities, organ volumes and blood
flow through each organ. Partition coefficients were kept the same as
for the rat model. Parameter uncertainties were handled by running
Fig. 4. (a) Shows the flutamide concentration as a function of time for plasma, liver, gonads and prostate in log scale, after an oral dosing of 5 mg/kg body weight to
the rats. (b) shows the AUC as a function of time for plasma, liver, gonads and prostate, after an oral dosing of 5 mg/kg body weight to the rats.
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multiple iterations with various values for each uncertain parameter in
parallel. This led to uncertainties in the predicted dynamic behavior of
flutamide concentrations in the various tissues.
When comparing to dynamic distribution of flutamide over seven
rat tissues, the model performed fairly: the median values predicted by
the model were less than a factor of 10 away from the average ex-
perimental value, for most tissues. In other words, the robustness of the
developed PBPK model for predicting flutamide levels in different
compartments was substantial. Although the model pointed out high
uncertainties in the predictions for some compartments (Fig. 3), the
observed concentrations were well captured by the predicted intervals
(within uncertainty range).
The uncertainty in the rat model predictions was about five times
larger than the experimental uncertainty, when evaluated at the 2.5;
97.5 percentile. Surprisingly, predictions for the human plasma levels,
although requiring more uncertain steps in model formulation was
actually better: the median model values were mostly less than a factor
of 4 away from the average experimental value, being the model un-
certainty equivalent with the experimental uncertainty. This suggests
that further average model refinement makes no sense, because of
limitations in the experimental values.
The limitations in the apparent accuracy of the experimental values
Fig. 5. PBPK model predictions of flutamide (A) and flutamide hydroxide (B) concentrations in human plasma following a 0.25 g oral dose of flutamide. Red lines:
median predictions; blue lines: 2.5 and 97.5 percentiles; gray lines: 20 random simulations from the ensemble of 15,000 iterations. The green dots and black lines
indicate the mean± sd concentrations reported in Radwanski et al. (1989). (For interpretation of the references to colour in this figure legend, the reader is referred
to the Web version of this article.)
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could be for either of two reasons: The experimental variability may be
due to experimental error, or due to biological variation between in-
dividuals. Inspecting the original experimental publications, we con-
clude that the latter explanation is the more likely one. This implies that
rather than looking into improvement of the model or for improvement
of the experimental methodology, one should begin to make the models
in an individualized way.
The extrapolation of the model to predicting flutamide kinetics in
humans with two scenarios of dosing (single and multiple) (Figs. 5 and
6) were also in good agreement with the observed data. Moreover, the
prediction of flutamide hydroxide and its agreement with observed data
(Figs. 5B and 6B), confirmed that the metabolic kinetics for the
production of metabolite in liver (flutamide hydroxide) and its dis-
tribution to the plasma was well captured. In the model, flutamide
hydroxide was confined to liver and plasma, not distributed over all the
given compartments owing to the fact of not having data on its bio-
distributions. In the worst case scenarios, it would be possible to dis-
tribute the flutamide hydroxide presuming its partition coefficient si-
milar with its parent compound or by prediction of its partition coef-
ficients using in-silico approach.
PBPK modeling have been used in inter-species, dose, duration and
specific population extrapolations for the risk assessment (Andersen,
1995; Andersen and Dennison, 2001; Evans et al., 2008; Thiel et al.,
2015). In this work, along with standard cross-species scaling approach
Fig. 6. PBPK model predictions of flutamide (A) and flutamide hydroxide (B) plasma concentration in human following a 0.25 g oral dose of flutamide at first day and
then 0.25 g three times a day on the 2nd to 8th day. Red lines: median predictions; blue lines: 2.5 and 97.5 percentiles; gray lines: 20 random simulations from the
ensemble of 15,000 iterations. The green dots and black lines indicate the mean± sd concentrations reported in Radwanski et al. (1989). (For interpretation of the
references to colour in this figure legend, the reader is referred to the Web version of this article.)
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Fig. 7. PBPK model predictions of flutamide concentration for 48hr in several human organs following a 0.25 g of single oral dose. Red lines: median predictions;
blue lines: 2.5 and 97.5 percentiles; gray lines: 20 random simulations from the ensemble of 15,000 iterations. (For interpretation of the references to colour in this
figure legend, the reader is referred to the Web version of this article.)
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we have harmonized the species specific metabolic parameters input for
developing the PBPK model. This was done by integrating in-vitro
metabolic kinetics based on IVIVE. The predictions of flutamide and its
metabolite flutamide hydroxide kinetics in human plasma for different
dose scenarios suggested that the dose dependency of flutamide kinetics
was modelled correctly. This might enhance the model's applicability
optimization of doses regimens based on not only the parent compound
(usual approach) but also its main metabolite flutamide hydroxide,
presumably responsible for pharmacological effects. The current model
could be useful for extrapolating low dose scenarios that are relevant
for environmental exposure of flutamide as a result of pharmaceutical
residuals as well as for verifying low dose animal testing endocrine
effects.
However additional research is required to better characterize the
flutamide kinetics: the dose dependency that we implemented in the
model is uncertain as flutamide is metabolized by two different en-
zymes namely carboxylesterase and arylacetamide deacetylase de-
pending on its concentration (Kobayashi et al., 2012a, 2012b;
Fig. 8. Normalized sensitivity coefficients for the dependence of plasma flutamide concentration 24 h after dosing on partition coefficient, Vmax's and KM's, as
obtained from simulated time course data of flutamide for 24hr. (A), represents sensitivity coefficients for rat PBPK and (B), represents sensitivity coefficients for
human PBPK.
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Watanabe et al., 2009). It should also be useful to measure the kinetics
of flutamide simultaneously in plasma and urine for the humans, as this
should give an additional mode of model validation. Although in this
study we have considered the metabolism of flutamide into three dif-
ferent metabolites (assuming hepatic clearance of flutamide), reported
studies shows that flutamide can produce even more metabolites in
humans, which could lead to a decrease in its own concentration. This
would allow for the confirmation of the total observed clearance of
flutamide (hepatic and renal) being faster experimentally than in the
present model. It also could allow the prediction of other important
metabolites as a function of flutamide exposure in the PBPK model and
reduce the uncertainties in parameters particularly associated with
metabolism and elimination to which the predicted flutamide con-
centration is sensitive (Fig. 8 and Table 2). Additionally, capturing
metabolic variation of flutamide due to variation in enzyme level at
target metabolizing tissue (liver), correlating with genetic predisposi-
tion, and accounting for changes in CYP activity, could enhance our
understanding at the level of a personalized PBPK model for flutamide
(Bordbar et al., 2015).
The results of this study are promising for application of PBPK
modeling in risk assessments of flutamide in human populations in the
context of target tissue concentration. To date, no tool has been de-
veloped to predict in humans the chemical kinetics in plasma and more
importantly tissues concentration along with time. Several future uses
of the PBPK model of flutamide could be considered. Here the model
could serve to relate the levels to which humans are exposed to the
levels attained in various target organs, suspected to be involved in
toxicity. By in vitro tissue-specific cell line experiments one could then
determine whether those levels should be expected to be toxic or tu-
morigenic for those tissues. In other words, the current model could be
used in a reverse dosimetry context to interpret the available in vitro
biomonitoring data so as to estimate the degree to which the population
is currently being exposed, an alternative solution to validate the esti-
mated PDE for flutamide for the pharmaceutical companies.
An important issue for EDCs is their idiosyncrasies, i.e. the phe-
nomenon that even if non-toxic for most of the human population, a
fraction of the population may suffer from exposure. One of the origins
of this idiosyncrasy may reside in inter-individual differences based on
genomic, nutritional or behavioral differences. Such idiosyncrasies are
often thought to occur in the PD, i.e. in the effect the EDC has on the
body. We suspect that idiosyncrasies may also arise in the PBPK, by
some individuals having strongly altered parameters in PD, such as
modelled by our model. In future work we shall account for mechanism
in our model (or in extended versions thereof) that are affected by
known single nucleotide polymorphisms (SNPs) in the human popula-
tion. These could reside in drug metabolism, or in drug pumping al-
terations.
Physiologically specific in nature, the current PBPK model for flu-
tamide could also be adapted to the context of a large human popula-
tion by considering their metabolic and genetic diversity. This could
add explanations of otherwise unexpected sensitivities of small frac-
tions of the population to flutamide and corresponding idiosyncrasies.
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